A. Y. Bedikian - Concepedia

Author

A. Y. Bedikian

The University of Texas MD Anderson Cancer Center

Also Known As

A Bedikian, A Y Bedikian, A. Bedikian, A. Y. Bedikian, A.Y. Bedikian, AY Bedikian

Publications

678

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Oncology Specialists

About

A. Y. Bedikian is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	147
2	Immunology	4	4	94
3	Health Sciences	2	2	23
4	Engineering	1	1	13
5	Chemistry	1	1	13

A. Y. Bedikian

Publications

580

Citations

H-Index

Page 1

	Year	Citations
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. Antônio C. Buzaid, Merrick I. Ross, Charles M. Balch, Journal of Clinical Oncology	1997	302
Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Sewa S. Legha, Sigrid Ring, Omar Eton, PubMed	1997	64
A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, ± dacarbazine (DTIC) in patients with metastatic melanoma (MM) Peter Hersey, Jeff Sosman, Steven O’Day, Journal of Clinical Oncology ImmunologyImmunotherapeuticsImmunotherapyHumanized Monoclonal AntibodyOncology	2005	55
Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Julie A. Ellerhorst, A. Y. Bedikian, Sigrid Ring, Oncology Reports	1999	49
Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma A. Y. Bedikian, Sewa S. Legha, Omar Eton, Annals of Oncology Surgical OncologyOncologyPhase Ii TrialMedicineMelanoma	1997	29
Sequential chemotherapy for adenocarcinoma of unknown primary A. Y. Bedikian, G. P. Bodey, M. Valdivieso, American Journal of Clinical Oncology	1983	18
Phase II study of volociximab (M200), an α5β1 anti-integrin antibody in metastatic melanoma Lee D. Cranmer, A. Y. Bedikian, Antoni Ribas, Journal of Clinical Oncology Endothelial CellsImmunologyPhase Ii StudyImmunotherapeuticsImmunotherapy	2006	15
Phase I study of aziridinylbenzoquinone (NSC 182986). A. Y. Bedikian, G. P. Bodey, M. A. Burgess, PubMed EngineeringNsc 182986Organic ChemistryPharmacotherapyMalignant Melanoma	1981	13
High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial Jon Richards, A. Y. Bedikian, René González, Journal of Clinical Oncology ImmunologyImmunoeditingAdvanced Metastatic MelanomaImmunotherapeuticsHigh-dose Allovectin-7	2005	12
A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM). Richard D. Carvajal, Mei Wong, John A. Thompson, Journal of Clinical Oncology Vegf Receptor-2Tumor BiologyPhase IiMedicineMelanoma	2010	12

Page 1